About UMGCC

2010 Fact Sheet

Overview:

The University of Maryland Marlene and Stewart Greenebaum Cancer Center is a National Cancer Institute-designated cancer center, one of the top cancer treatment and research centers in the country. We offer innovative approaches to diagnosing and treating all types of cancer; conduct cutting-edge research to bring the latest advances in cancer treatment directly to our patients; and provide cancer screening and patient education services.


National Recognition:

Outstanding Patient Care:

  • A team approach to care – specialists from all cancer disciplines work together to develop an individualized treatment plan for each patient
    • At a Glance
    Patient visits annually 45,000
    Clinical trials 150
    Physicians and researchers 211
    Research funding $62 million
  • Minimally invasive treatment options – including Trilogy for radiation therapy, da Vinci robot-assisted surgery and the newest, targeted drug therapies
  • Patient-focused Stoler Pavilion outpatient center – designed for patients’ comfort and convenience, with flat-screen TVs and Internet access
  • Top-rated nursing staff – specially trained in cancer care and consistently rated outstanding in patient satisfaction surveys
  • Support services for patients – including two full-time patient navigators, genetic and nutrition counseling,image renewal center and acupuncture for symptom management
  • Community outreach – free breast, cervical and colorectal cancer screenings for uninsured, low-income Baltimore residents through our Baltimore City Cancer Program

Scientific Excellence:

  • Major advances in cancer research – including Dr. Angela Brodie’s discovery of aromatase inhibitors, a new class of drugs for treating women with breast cancer, and Dr. Kevin Cullen’s landmark study linking HPV to racial disparities in head-and-neck cancer survival
  • Pioneering stem cell and HIV/AIDSrelated cancer studies – in partnership with the University of Maryland Center for Stem Cell Biology and Regenerative Medicine and the Institute of Human Virology
  • Innovative clinical trials – 150 active studies offering patients promising therapies, often years before they are available commercially
  • Active translational research program – designed to speed scientific discoveries from the laboratory to the clinic for the benefit of patients
  • State-of-the-art laboratories – where our researchers are developing cancer vaccines, novel cancer-fighting agents and promising combination therapies
  • Commitment to addressing cancer disparities – with research focused on improving access to care and treatment outcomes for minorities, who represent 36 percent of the patients in our clinical trials (compared to 2 percent nationally)
  • Major partnerships – with the state of Maryland, the National Cancer Institute, the American Cancer Society and private industry

Comprehensive Treatment Programs:


This page was last updated on: June 29, 2010.